CliffBio
small molecule

GENVOYA

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Loss of exclusivityApril 2033latest FDA-listed patent expiry
CompanyGilead Sciences →View the full company profile on CliffBio

Drug detail

Brand nameGENVOYA
Active ingredientCOBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Strength150MG;150MG;200MG;EQ 10MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2015
Marketing statusRX

Listed patents

PatentExpiresType
10039718*PEDApril 2033—
9296769*PEDFebruary 2033—
8754065*PEDFebruary 2033—
10039718October 2032product
8754065August 2032substance, product
9296769August 2032substance, product
8633219*PEDOctober 2030—
8633219April 2030product
8148374*PEDMarch 2030—
9891239*PEDMarch 2030—
9891239September 2029product
8148374September 2029substance, product
8981103*PEDApril 2027—
7635704*PEDApril 2027—
7176220*PEDFebruary 2027—
8981103October 2026substance, product
7635704October 2026substance, product
7176220August 2026substance, product

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

GENVOYA patent cliff — loss of exclusivity April 2033 | CliffBio